Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with etoposide for recurrent small cell lung cancer
ChiCTR1800017464Phase 4Recruiting
- Sponsor
- Jinhua Guangfu Hospital
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and etoposide in small cell lung cancer (SCLC), sponsored by Jinhua Guangfu Hospital. Primary endpoint: Progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranibetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR1800017464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017464.